Research governance and bureaucracy for multisite studies: implications for occupational therapy research

Whitehead, Phillip; Drummond, Avril; Fellows, Karen
July 2011
British Journal of Occupational Therapy;Jul2011, Vol. 74 Issue 7, p355
Academic Journal
Obtaining research governance approvals for research involving the National Health Service (NHS) has become increasingly complex. In order to obtain the necessary approvals to interview 20 occupational therapists from a range of locations across the United Kingdom, the authors had to submit lengthy applications to all 20 sites. Before issuing their approvals, some sites raised numerous queries, whilst others did not raise any. The time taken to obtain approvals ranged from 6 to 197 days. These disparities highlight that the current research governance procedure for multisite studies is complex and subject to local interpretations. This opinion piece argues that the procedure is excessive for research that does not involve patients and involves NHS staff only. It also argues that this is an injudicious use of resources at a time of national austerity. Implications for the future of occupational therapy research in the United Kingdom are discussed.


Related Articles

  • Groups finding common ground on Common Rule.  // IRB Advisor;Dec2011, Vol. 11 Issue 12, p129 

    No abstract available.

  • Neurology research network starts IRB review.  // IRB Advisor;Jun2012, Vol. 12 Issue 6, p66 

    The article discusses NeuroNEXT, a network developed by the National Institute of Neurological Disorders and Strokes (NINDS). The network coordinates institutional review board (IRB) reviews for institutions across the country in order to conduct trails of neurological therapies. It explains how...

  • CNE/CME QUESTIONS.  // IRB Advisor;8/1/2012, p96 

    A quiz on CNE/CME questions regarding enrollment informed consent comprehension, IRB's option of conducting local reviews of the study and the only socioeconomic or demographic factor that remained an independent predictor of clinical trial participation is presented.

  • Adaptive design: Points to consider.  // IRB Advisor;Jul2010, Vol. 10 Issue 7, p80 

    The article discusses the aspects to be considered in the use of adaptive design. Several issues concerning the Institutional Review Board (IRB) which can be affected by adaptive design are cited, which include informed consent of research participants and the misconceptions on the difference...

  • Strategies for handling poorly-written protocols.  // IRB Advisor;Dec2008, Vol. 8 Issue 12, p138 

    The article offers tips for investigators on how to handle poorly-written protocols. According to Michelle Gibel, institutional review board (IRB) administrator at Rutgers, many informed consent (IC) forms are written in language that does not meet the criteria of being readable at a sixth to...

  • Seven key features of UCLA consent form.  // IRB Advisor;Dec2008, Vol. 8 Issue 12, p141 

    The article discusses the seven key features of the consent form from the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles (UCLA) Medical Center. The consent form has a three-page template that institutional review board (IRB) staff analysts use when...

  • Bridging the Divide between Genomic Science and Indigenous Peoples. Jacobs, Bette; Roffenbender, Jason; Collmann, Jeff; Cherry, Kate; Lee Bitsói, LeManuel; Bassett, Kim; Evans, Charles H. // Journal of Law, Medicine & Ethics;Fall2010, Vol. 38 Issue 3, p684 

    The new science of genomics endeavors to chart the genomes of individuals around the world, with the dual goals of understanding the role genetic factors play in human health and solving problems of disease and disability. From the perspective of indigenous peoples and developing countries, the...

  • Nanomedicine First-in-Human Research: Challenges for Informed Consent. King, Nancy M. P. // Journal of Law, Medicine & Ethics;Winter2012, Vol. 40 Issue 4, p823 

    Risks of harm, translational uncertainty, ambiguities in potential direct benefit, and long-term follow-up merit consideration in first-in-human research. Some nanomedical technologies have additional characteristics that should be addressed, including: defining and describing nanomedical...

  • Views differ on HIV research in the developing world.  // IRB Advisor;Apr2009, Vol. 9 Issue 4, p44 

    The article discusses a survey of the U.S. Institutional Review Board (IRB) and South African research ethics committee (REC) related to the human immunodeficiency virus (HIV) research. Robert Klitzman believes that there is a need to understand the problems of IRB about handling research in a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics